文献速递认知障碍与痴呆

GLP-1RA与SGLT2i药物与2型糖尿病患者的阿尔茨海默病及相关痴呆风险

GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias.
PubMed 文献 · JAMA Neurol · 2025-01-01

本研究采用目标试验模拟方法,基于OneFlorida+临床研究联盟2014年1月至2023年6月的电子健康记录数据,纳入50岁及以上、无既往ADRD诊断或抗痴呆治疗的2型糖尿病患者。结果显示,与其它降糖药相比,GLP-1RA和SGLT2i启动者ADRD发生率均显著降低,但两药之间无差异。

要点

  • 在2型糖尿病患者中,GLP-1RA启动者ADRD发生率低于其他降糖药启动者(HR 0.67)。
  • SGLT2i启动者ADRD发生率也低于其他降糖药启动者(HR 0.57)。
  • GLP-1RA与SGLT2i两药之间ADRD风险无显著差异(HR 0.97)。

核心结论

  • 在2型糖尿病患者中,与其它降糖药相比,GLP-1RA和SGLT2i均与ADRD风险显著降低相关,且两药之间未观察到差异。

研究设计与样本

  • 本研究为目标试验模拟研究,使用OneFlorida+临床研究联盟2014年1月至2023年6月的电子健康记录数据。
  • 患者年龄≥50岁,无既往ADRD诊断或抗痴呆治疗。

主要发现

  • GLP-1RA vs 其他降糖药队列:GLP-1RA启动者ADRD发生率较其他降糖药启动者降低,率差为-2.26/1000人年(95%CI -2.88至-1.64),HR 0.67(95%CI 0.47-0.96)。
  • SGLT2i vs 其他降糖药队列:SGLT2i启动者ADRD发生率较其他降糖药启动者降低,率差为-3.05/1000人年(95%CI -3.68至-2.42),HR 0.57(95%CI 0.43-0.75)。
  • GLP-1RA vs SGLT2i队列:两药之间ADRD发生率无差异,率差为-0.09/1000人年(95%CI -0.80至0.63),HR 0.97(95%CI 0.72-1.32)。

关键数值与推荐

  • ADRD通过临床诊断代码识别。
  • 使用Cox比例风险回归模型并采用逆概率治疗加权(IPTW)调整潜在混杂因素,估计风险比(HR)及95%CI。

局限性

  • 原文未述局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) and risk of Alzheimer disease and related dementias (ADRD) remains to be confirmed. OBJECTIVE: To assess the risk of ADRD associated with GLP-1RAs and SGLT2is in people with type 2 diabetes (T2D). DESIGN, SETTING, AND PARTICIPANTS: This target trial emulation study used electronic health record data from OneFlorida+ Clinical Research Consortium from January 2014 to June 2023. Patients were 50 years or older with T2D and no prior diagnosis of ADRD or antidementia treatment. Among the 396 963 eligible patients with T2D, 33 858 were included in the GLP-1RA vs other glucose-lowering drug (GLD) cohort, 34 185 in the SGLT2i vs other GLD cohort, and 24 117 in the GLP-1RA vs SGLT2i cohort. EXPOSURES: Initiation of treatment with a GLP-1RA, SGLT2i, or other second-line GLD. MAIN OUTCOMES AND MEASURES: ADRD was identified using clinical diagnosis codes. Hazard ratios (HRs) with 95% CIs were estimated using Cox proportional hazard regression models with inverse probability of treatment weighting (IPTW) to adjust for potential confounders. RESULTS: This study included 33 858 patients in the GLP-1RA vs other GLD cohort (mean age, 65 years; 53.1% female), 34 185 patients in the SGLT2i vs other GLD cohort (mean age, 65.8 years; 49.3% female), and 24 117 patients in the GLP-1RA vs SGLT2i cohort (mean age, 63.8 years; 51.7% female). In IPTW-weighted cohorts, the incidence rate of ADRD was lower in GLP-1RA initiators compared with other GLD initiators (rate difference [RD], -2.26 per 1000 person-years [95% CI, -2.88 to -1.64]), yielding an HR of 0.67 (95% CI, 0.47-0.96). SGLT2i initiators had a lower incidence than other GLD initiators (RD, -3.05 per 1000 person-years [95% CI, -3.68 to -2.42]), yielding an HR of 0.57 (95% CI, 0.43-0.75). There was no difference between GLP-1RAs and SGLT2is, with an RD of -0.09 per 1000 person-years (95% CI, -0.80 to 0.63) and an HR of 0.97 (95% CI, 0.72-1.32). CONCLUSION AND RELEVANCE: In people with T2D, both GLP-1RAs and SGLT2is were statistically significantly associated with decreased risk of ADRD compared with other GLDs, and no difference was observed between both drugs.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Tang H, Donahoo WT, DeKosky ST, et al. GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias. JAMA Neurol. 2025. PMID: 40193118. doi:10.1001/jamaneurol.2025.0353

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。